The Christie NHS Foundation Trust (Christie) - United Kingdom
The Christie NHS Foundation Trust is the main tertiary oncology centre for the North West of England, treating more than 40,000 patients a year and officially accredited as a European comprehensive cancer centre. It is a major research site, having strong links with the University of Manchester and sharing the campus with the CRUK Patterson Laboratories and the Wolfson Molecular Imaging Centre. It is part of the Manchester Cancer Research Centre and a partner in the Manchester Academic Health Sciences Research Centre.
The Trust has delivered a Molecular Radionuclide Therapy (MRT) service for more than 30 years and, over the last decade, has developed experience and recognition in the delivery of Radio-ImmunoTherapy (RIT) led by the Professor of Targeted Therapy and Oncology, Tim Illidge. It now offers an extensive service, including well established Radiology led Selective Internal Radiotherapy (SIRT) and MRT for Neuroendocrine cancers.
The Nuclear Medicine group has developed dosimetry experience during collaborations in multicentre RIT trials [1-4] and this is now being used in other trials and routine therapies.
Role and main tasks in the JRP
The Nuclear Medicine group will participate, as unfunded JRP-Partners, in WP2 (Quantitative Imaging for MRT), WP3 (Measurement of absorbed dose from radionuclides) and, to a lesser extent, WP4 (Modelling and uncertainty analysis) of the JRP.
For more information: Contact Vere Smyth
